You are here: Industry Insights > Razuprotafib

News List

Quantum Leap Healthcare Discontinues Razuprotafib I-SPY COVID Trial americanpharmaceuticalreview
March 11, 2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio drug, razuprotafib.
Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients prnewswire
September 03, 2020
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute ...
Aerpio, Quantum Leap Select Razuprotafib as Potential Treatment for COVID-19 ARDS americanpharmaceuticalreview
June 02, 2020
Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative™ announced an agreement has been reached to evaluate razuprotafib in a new randomized ...